Dr. Xiaona Wang 王晓娜
Chief Physician
Department of Gastric Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gastrointestinal tumors, including gastric cancer, GIST, lymphoma, neuroendocrine tumors, colon cancer, small bowel tumors, and retroperitoneal masses. Expertise in laparoscopic and open gastrectomy, combined organ resection, neoadjuvant therapy, intraperitoneal hyperthermic chemotherapy, digestive tract reconstruction, and targeted therapy for GIST.
Dr. Wang holds a medical doctorate from China Medical University (1997) and has worked at Tianjin Medical University Cancer Institute & Hospital since 1997. A visiting scholar at Japan Cancer Institute Hospital, Dr. Wang has led research projects, won the Tianjin Science and Technology Progress Award (Third Class), and guided a team to the 2018 National Championship in the Qiusuo Super Team Competition.
Professional roles
- Youth Committee Member, Gastrointestinal Stromal Tumor (GIST) Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Gastric Cancer Professional Committee, Tianjin Anti-Cancer Association
- Secretary-General, Gastric Cancer Professional Committee, Tianjin Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Xiaona). Papers usually list the name as Xiaona Wang or Wang X.
Selected publications
24 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin Med J (Engl), 2025 (senior author): Efficacy and safety of using an enteral immunonutrition formula in the enhanced recovery after surgery protocol for Chinese patients with gastrointestinal cancers undergoing surgery: A randomized, open-label, multicenter trial (healing trial). PubMed 40653996
- iScience, 2024 (senior author): Revealing splenectomy-driven microRNA hsa-7b-5p's role in pancreatic cancer progression. PubMed 38361622
- FEBS Open Bio, 2018 (first author): Dasatinib promotes TRAIL-mediated apoptosis by upregulating CHOP-dependent death receptor 5 in gastric cancer. PubMed 29744288
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion